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David E. James 2,3, Markus A. Ruegg 5, Erik A. Richter 1,*ABSTRACT
The effect of acute inhibition of both mTORC1 and mTORC2 on metabolism is unknown. A single injection of the mTOR kinase inhibitor,
AZD8055, induced a transient, yet marked increase in fat oxidation and insulin resistance in mice, whereas the mTORC1 inhibitor rapamycin
had no effect. AZD8055, but not rapamycin reduced insulin-stimulated glucose uptake into incubated muscles, despite normal GLUT4
translocation in muscle cells. AZD8055 inhibited glycolysis in MEF cells. Abrogation of mTORC2 activity by SIN1 deletion impaired glycolysis and
AZD8055 had no effect in SIN1 KO MEFs. Re-expression of wildtype SIN1 rescued glycolysis. Glucose intolerance following AZD8055
administration was absent in mice lacking the mTORC2 subunit Rictor in muscle, and in vivo glucose uptake into Rictor-deficient muscle was
reduced despite normal Akt activity. Taken together, acute mTOR inhibition is detrimental to glucose homeostasis in part by blocking muscle
mTORC2, indicating its importance in muscle metabolism in vivo.
 2014 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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The mammalian target of rapamycin (mTOR) protein is the catalytic
subunit for two functionally and structurally distinct mTOR com-
plexes (mTORC1 and mTORC2) [1]. mTORC1 is a major regulator of
protein synthesis and cell growth [1]. Less is known, especially
in vivo, about the more recently discovered mTORC2, but in the
central nervous system, the liver and fat tissue it regulates glucose
metabolism [2e5]. mTORC2 is also a major upstream kinase for the
Akt Ser473 residue [6].
Understanding mTOR biology is vital in cancer, metabolism and aging
research. Hyper-activated mTOR is common and possibly causal in
cancer, because mutations of negative upstream regulators of the
mTOR pathway lead to tumorigenesis [7]. Knockout of the mTOR target
S6K1 [8] or long-term mTOR blockade by rapamycin treatment [9e13]
extends lifespan in mice. However, other reports have shown detri-
mental health effects like insulin resistance and reduction in beta-cell
mass following prolonged rapamycin treatment [14e19].
The tools to study mTOR biology on a whole-body level in mice are
limited because knockout (KO) of mTOR is embryonic lethal and
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[20]. Chronic rapamycin treatment can abrogate mTORC2 activity [21],
and insulin resistance in mice treated with rapamycin for several
weeks has been attributed to impaired liver mTORC2 activity [19]. In
other long-term rapamycin studies, however, in which rodents also
exhibited insulin resistance, mTORC2 activity was normal judged by
liver Akt S473 phosphorylation [15,17,18]. Moreover, different dura-
tions of chronic rapamycin treatment lead to different phenotypes
along with varying degrees of mTORC2 activity [15]. Therefore, while
the effects of rapamycin remain important to study, it may not be the
best tool to study mTOR signaling per se.
A new generation of mTOR kinase inhibitors (mTOR-KI) acutely and
potently inhibits both mTOR complexes, but the in vivo effects on
metabolism have not been extensively investigated. These mTOR KIs
are ATP-competitive mTOR inhibitors, whereas rapamycin forms a
complex with FKBP12 to allosterically inhibit mTORC1. We used the
mTOR-KI AZD8055 to study the effects of acute mTOR inhibition on
glucose metabolism. We contrasted our findings to acute rapamycin
treatment to seek out AZD8055 effects due to mTORC2 inhibition,
which we further explored by using genetic mTORC2 KO models (SIN1
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2. MATERIALS AND METHODS
2.1. Animals
Female C57BL/6 mice (Taconic, Denmark) aged 11e12 weeks old
were used, as well as female muscle specific Rictor knockout (mKO:
RictorFloxed/Floxed, HSA-Cre/þ) and wildtype (WT: RictorFloxed/Floxed,
HSA-Cre/) littermates, aged 11e14 weeks. Generation of these
mice has been described elsewhere [22]. Animals were kept on a
12:12-h lightedark cycle and had free access to standard rodent chow
diet (Altromin no. 1324; Chr. Pedersen, Denmark) and water. All mice
were group-housed. All experiments were approved by the Danish
Animal Experimental Inspectorate and complied with the terms of the
“European Convention for the Protection of Vertebrate Animals Used for
Experiments and Other Scientific Purposes.”
2.2. In vivo AZD8055 and rapamycin injection experiments
AZD8055 and rapamycin (Selleckchem, Houston, USA) were formu-
lated according to Chresta et al. [23] and Chen et al. [10], respectively.
In brief, AZD8055 was prepared at 1 mg/ml in a 30% (w/v) Captisol
(Ligand Pharmaceuticals, Inc, La Jolla, CA, USA) solution and the pH
was adjusted to 3. For vehicle injections, 30% (w/v) Captisol, pH3,
was used. For rapamycin, a rapamycin stock solution (12.5 mg/ml in
ethanol) was diluted to 0.4 mg/ml in 5% (w/v) Tween-80 and 5% (w/v)
polyethylene glycol (PEG) (SigmaeAldrich). For vehicle injections a 5%
(w/v) Tween-80 and 5% (w/v) PEG solution was used. For all treat-
ments 10 ml per gram mouse mass were injected. Mice were accli-
matized to indirect calorimetry cages (PhenoMaster, TSE, Bad
Homburg, Germany) for 3 days. After an overnight fast, mice were
intraperitoneal (IP)-injected with vehicle or AZD8055 (10 mg kg1)
[23]; or vehicle or rapamycin (4 mg kg1) [10] and given free access to
food for 6 h. Expired carbon dioxide (VCO2) and inhaled oxygen (VO2)
were measured to calculate respiratory exchange ratio (RER). Calcu-
lations of carbohydrate and fat utilization were adopted from Couture
et al. [24] and normalized to mouse body mass. For plasma glucose
determination, mixed tail blood was obtained at baseline, after an
overnight fast and at 1, 3, 6, and 24 h following AZD8055 injection,
during which mice had free access to food, and analyzed in duplicates
with a glucometer (Contour XT, Bayer Consumer Care AG, Basel,
Switzerland). For plasma insulin determination at the 3 h time-point
mixed tail blood was collected into heparinized capillary tubes and
plasma insulin levels were assayed with an ELISA kit (Mouse Ultra-
sensitive Insulin ELISA, #80-INSMSU-E01, Alpco, Salem, USA). Plasma
fatty acids (FAs) were determined with a colorimetric commercial kit
(NEFA-HR(2) kit, Wako Chemicals, Germany) using a Hitachi 912
Automatic Analyzer, Germany. For glucose tolerance test Rictor WT and
mKO mice were fasted for three hours, injected with vehicle or
AZD8055, and two hours later IP-injected with 2 g/kg bodyweight D-
glucose (0.2 g in 1 ml saline). Blood glucose concentration in mixed tail
blood was measured in duplicates with a glucometer just before drug
and glucose injection (120 and 0 min, respectively) and 20, 40, 60,
90 and 120 min after glucose injection. For the signaling experiment
mice were overnight fasted, injected with vehicle or AZD8055 and
granted free access to food. Two hours after injection mice were
euthanized by cervical dislocation and gastrocnemius, quadriceps,
liver, heart and gonadal adipose tissue were quickly dissected out and
stored at 80 C.
2.3. In vitro mouse muscle incubations and 2-deoxyglucose (2-DG)
uptake
Soleus and EDL muscles from both legs were dissected out from 1 h
fasted and anesthetized mice (6 mg pentobarbital and 0.24 mgMOLECULAR METABOLISM 3 (2014) 630e641  2014 The Authors. Published by Elsevier GmbH. This is an ope
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after muscles had been removed. Muscles were gently lengthened to
resting tension (4e5 mN) in incubation chambers (Multi Myograph
system; Danish Myo-Technology, Denmark). As described previously
[25], these chambers contained 4 ml heated (30 C) KrebseRingere
Henseleit (KRH) buffer supplemented with 2 mM pyruvate, 8 mM
mannitol and 0.1% BSA. Muscles were incubated for 60 min with
either 0.1% DMSO, 640 nM AZD8055 or 1 mM Rapamycin. When
appropriate, insulin (Actrapid, Novo Nordisk, Bagsvaerd, Denmark) was
added during the last 30 min of inhibitor and DMSO presence, resulting
in an insulin concentration of 60 nM. During the last 10 min of insulin
stimulation 2-DG uptake was measured with 3H-2-DG and
14C-Mannitol radioactive tracers and 1 mM of 2-DG [25]. Muscles were
washed in ice-cold KRH buffer, blotted dry and snap-frozen in liquid
nitrogen, trimmed and weighed, before stored at 80 C.
2.4. 2-DG uptake and GLUT4 translocation and signaling in L6
myoblasts
L6 cells stably over-expressing GLUT4 with a c-myc epitope tag (L6-
GLUT4myc) [26], a kind gift from Amira Klip, were grown in a-MEM
media (GIBCO #1257-063) with 10% fetal bovine serum (GIBCO
#26140-038), 100 units/mL penicillin, 100 mg/mL streptomycin,
0.25 mg/ml Fungizone (GIBCO #15240-062) (5% CO2, 37 C). For
uptake, translocation and signaling experiments cells were grown until
confluent and the following experimental scheme was applied: Cells
were serum starved for four hours. During the last 50 min of starvation,
inhibitors (0.1%DMSO, 500 nM AZD8055 or 100 nM Rapamycin) were
added. Twenty minutes before the end of starvation, insulin (10 or
100 nM) was added when appropriate. 2-DG uptake over five minutes
was then determined as previously described by Somwar et al. [27]
and related to protein concentration in each well. Background deter-
mined with cytochalasin B was subtracted and experiments were
assayed in duplicates. For the GLUT4 translocation assay, the media
was removed at the end of basal or insulin stimulation and cells were
immediately chilled on ice, fixed with 3% paraformaldehyde, blocked
in 5% goat serum, and incubated with primary anti-myc antibody
(Cell Signaling Technology). The signal was detected with a secondary
HRP-antibody and o-Phenylenediamine reagent (SigmaeAldrich) was
added to each well to initiate a color reaction with the secondary
antibody. This was terminated with 5 M HCl, before absorbance at
492 nm was measured. Background absorbance (no primary antibody)
was subtracted. Each experiment was assayed in at least triplicates.
2.5. Glucose transport into giant sarcolemmal vesicles from rats
To investigate whether AZD8055 has direct effect on glucose trans-
porters, giant sarcolemmal vesicles (GSV) were prepared from rat
gastrocnemius muscle from four pooled rats as previously described
[28]. For the glucose transport experiment, aliquots of freshly prepared
GSV suspension were pre-incubated in KCleMOPS buffer (140 mM KCl
and 10 mM MOPS) with or without 640 or 1280 nM AZD8055 for
15 min at RT. Uptake medium was added for 45 s to yield a final
concentration of 0.5 mCi ml1 3H-2-deoxyglucose (2DG), 0.1 mCi ml1
14C-Mannitol, 5 mM 2DG and 35 mM Mannitol (all in KCleMOPS
buffer). Glucose transport was terminated by adding ice-cold stop
solution (KCleMOPS containing 50 mM cytochalasin B). Specific
glucose transport was calculated as the difference between total
3H-2DG and extravesicular 3H-2DG.
2.6. Western blot analysis
Tissues were homogenized 3  30 s at 30 Hz using a Tissuelyser II
(Qiagen, USA) in ice-cold homogenization buffer (10% Glycerol, 20 mMn access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/). 631
Original articleNa-pyrophosphate, 150 mM NaCl, 50 mM HEPES (pH 7.5), 1% NP-40,
20 mM b-glycerophosphate, 10 mM NaF, 2 mM PMSF, 1 mM EDTA (pH
8.0), 1 mM EGTA (pH 8.0), 10 mg/ml Aprotinin, 10 mg/ml Leupeptin,
2 mM Na3VO4, 3 mM Benzamidine). Homogenates were rotated end-
over-end for 1 h, before lysate supernatant was obtained by centrifu-
gation for 20 min at 13,000  g at 4 C. Lysate protein content was
determined with the bicinchoninic acid (BCA) method using BSA stan-
dards (Pierce) and BCA assay reagents (Pierce) and all lysates were
diluted to the same protein concentration. Lysates from the adipose
tissue from the in vivo AZD8055 injection experiment were pooled (two
animals together for n ¼ 1), because of the small amount of lysates
obtained for these particular samples. Total protein and phosphorylation
levels of indicated proteins were determined by standard immuno-
blotting technique loading equal amounts of protein (5e40 mg). The
primary phospho-antibodies used were p-AktSer473 (#9271), p-AktThr308
(#9275), p-NDRG1Thr346 (#3217), p-p70S6k1Thr389 (9205), phospho-
Akt Substrate (PAS) (#9614) (Cell Signaling Technology, all rabbit).
The primary total antibodies used were beta-actin (#4967, Cell
Signaling, rabbit), Akt2 (#2964, Cell Signaling, rabbit), p70S6K1
(#9202, Cell Signaling, rabbit), GSK3-beta (#610201, BD Bioscience,
mouse), AS160 (#07-741, Millipore, rabbit), GLUT4 (#PA11065, Affinity
Bioreagents, rabbit) and NDRG1 (ab37897, Abcam, goat). Poly-
vinylidene difluoride membranes (Immobilon Transfer Membrane; Mil-
lipore) were blocked in TBS-Tween 20 containing 5% skim milk or 3%
BSA protein for 20 min at room temperature. Membranes were incu-
bated with primary antibodies overnight at 4 C, followed by incubation
with horseradish peroxidase-conjugated (HRP) secondary antibody
(Jackson ImmunoResearch Laboratories) for 45 min at room temper-
ature. Bands were visualized in a BIO-RAD ChemiDoc MP Imaging
System after incubation with enhanced chemiluminescence (ECLþ;
Amersham Biosciences).
2.7. SIN1 cell work
SIN1 KO MEFs were a kind gift from Bing Su. WT HA-SIN1 was re-
expressed in SIN1/ MEFs using the pMIG retrovirus vector which
co-expresses GFP with HA-SIN1. 48 h after infection, GFP-positive
cells were isolated by fluorescence-activated cell sorting. WT MEFs,
SIN1/ and SIN1/ MEFs reexpressing HA-SIN1 were washed
and treated for 16 h in 0.1% FCS, or in 10% FCS supplemented with
0.1% DMSO, 10 mM Akt inhibitor MK2006 or 500 nM AZD8055 as
indicated. Media lactate levels were measured using the hydrazine
sink method, as described previously [29], and normalized to cellular
protein levels, measured using the BCA assay (Pierce).
2.8. In vivo glucose-induced glucose uptake and glycogen and
muscle glucose determinations
Baseline mixed tail blood was collected from conscious and overnight-
fasted (w12 h) mice, before mice were IP injected (10 ml/kg body
mass) with either saline or glucose (2 g/kg body mass) containing
0.1 mM 2-deoxyglucose (2-DG) and 60 mCi/ml 3H-labeled-2-DG [30].
Additional blood was drawn at 15 and 30 min post-injection. Imme-
diately after the last blood draw mice were sacrificed by cervical
dislocation and quadriceps muscles were rapidly excised and snap
frozen in liquid nitrogen. The blood draws were used for blood glucose
and plasma insulin determinations, which were carried out as
described above. In addition, 10 ml of plasma was used to measure the
plasma 3H activity by scintillation counting. Subsequently the area
under the curve, AUC 3H-2-DG0e30 min, was calculated by the trapezoid
method to estimate the 3H-2-DG levels the muscles had been exposed
to [30]. Fifty milligrams of quadriceps muscle was used to determine
the accumulation of phosphorylated 3H-2-DG (3H-2-DG-6-P) with the632 MOLECULAR METABOLISM 3 (2014) 630e641  2014 The Authors. Published by Elsevier Gmprecipitation method [30]. Quadriceps muscle glycogen content was
measured as glycosyl units after acid hydrolysis and muscle glucose
was determined fluorometrically from neutralized perchloric acid ex-
tracts [31].
2.9. Statistical analysis
The error bars represent SEM. Statistical testing was performed using
two-tailed Student t-tests when comparing two means. Analysis of
variance (ANOVA) or, when experiments involved multiple testing,
repeated measures ANOVA with Holm Sidak post hoc tests were
performed when comparing more than two means. Statistical evalu-
ation was performed using SigmaPlot 11.0. The significance level was
set at p <0.05.
3. RESULTS
3.1. AZD8055 but not rapamycin alters substrate utilization in vivo
We injected AZD8055 or rapamycin at doses used in preclinical cancer
mouse studies [10,23] into fasted C57BL/6 mice and measured
metabolic flexibility with indirect calorimetry during re-feeding.
AZD8055, but not rapamycin, markedly decreased the respiratory
exchange ratio (RER) (Figure 1A,B) without alterations in food con-
sumption (Figure 1C,D). AZD8055 treated mice had reduced carbo-
hydrate and increased fat utilization (Supplemental Figure 1a,b), while
rapamycin treated mice showed no changes (Supplemental
Figure 1c,d).
3.2. AZD8055 induces insulin resistance in vivo
Glucose levels in AZD8055 injected mice were elevated 3 and 6 h after
drug injection but were similar to control mice at 24 h after drug in-
jection (Figure 2A). Along with elevated glucose levels at 3 h, AZD8055
treated mice had 3-fold higher plasma insulin levels (Figure 2B) and
lower plasma FAs (Figure 2C). These data indicate whole-body insulin
resistance and suggest an increased reliance on FAs as an energy
substrate in agreement with the indirect calorimetry data (Figure 1A).
3.3. AZD8055 reduces mTOR and Akt signaling in vivo
AZD8055 injection blocked phosphorylation of the mTORC1 readout
p70S6K1Thr389, the mTORC2 substrate, AktSer473, and the mTORC2
biomarker, NDRG1Thr346 in skeletal muscle, adipose tissue, liver, and
cardiac muscle 2 h after injection (Figure 2DeF). Phosphorylation of
AktThr308, which is essential for full Akt kinase activation and may
regulate p-AktSer473 [32], was unaffected by AZD8055 in skeletal
muscle and liver tissue and increased in cardiac muscle and adipose
tissue (Figure 3A). Phosphorylation of Akt substrate of 160 kDa
(AS160), an Akt target and a key mediator of insulin-induced glucose
uptake [33,34] was unchanged in skeletal and cardiac muscle
following mTOR inhibition (Figure 3B). p-AS160 was decreased
following AZD8055 treatment in adipose tissue whereas it was un-
detectable in liver (Figure 3B). AZD8055 injection had largely no effect
on the amount of total AS160, p70S6K1, Akt2 and NDRG1 expression
detected by immunoblotting (Supplemental Figure 2), except for a 9%
decrease in gastrocnemius p70S6K1 levels (Supplemental Figure 2c)
and a 30% decrease in adipose tissue AS160 levels (Supplemental
Figure 2b).
3.4. AZD8055 but not rapamycin impairs insulin-stimulated
glucose uptake in vitro
Acute AZD8055 treatment (1 h) impaired insulin-stimulated glucose
uptake in soleus and EDL muscle byw30%, while rapamycin (1 h) had
no effect (Figure 4A,B). Basal glucose uptake was unaffectedbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Figure 1: AZD8055 treatment alters fuel substrate utilization in vivo. (A,B) Overnight fasted mice were intraperitoneal-injected with vehicle or AZD8055 (10 mg kg1); or vehicle or
rapamycin (4 mg kg1) before re-feeding was initiated. Respiratory exchange ratio (RER) was measured (n ¼ 3e4). (C,D) Food eaten throughout 6 h of re-feeding in the AZD8055
and rapamycin experiment (n ¼ 3e4). #p < 0.05 different from vehicle at indicated time points. Data are means  SEM.suggesting GLUT1 function was unperturbed by the mTOR blockers
(Figure 4A,B). Similar to the in vivo effects, AZD8055 treatment
inhibited readouts of both mTOR complexes (p70S6K1Thr389, AktSer473,
NDRG1Thr346) (Figure 5BeD, GeI). Acute rapamycin only inhibited the
mTORC1 readout p-p70S6K1Thr389 (Figure 5D,I), but to a lesser extent
than AZD8055. In contrast to in vivo, AZD8055 decreased p-AktThr308
in both soleus and EDL muscles (Figure 5E,J). Rapamycin enhanced
insulin-stimulated p-AktThr308 in soleus, but had no effect in EDL
muscle (Figure 5E,J). p-AS160 was insulin responsive, but was not
affected by the mTOR inhibitors in either soleus or EDL muscle
(Figure 5F,K). AZD8055 or Rapamycin treatment had no effect on total
protein expression of Akt2, NDRG1, AS160, and p70S6K1
(Supplemental Figure 3). However, insulin treatment increased the
amount of total AS160 detected by immunoblotting by w23% and
w21% in soleus and EDL muscle, respectively (Supplemental
Figure 3c,h).
3.5. AZD8055 reduces glucose uptake but not GLUT4 translocation
and activity
AZD8055 reduced glucose uptake in L6 muscle cells during insulin
stimulation (100 nM), while rapamycin had no effect (Figure 6A,B). This
inhibitory effect on glucose uptake occurred despite normal insulin-MOLECULAR METABOLISM 3 (2014) 630e641  2014 The Authors. Published by Elsevier GmbH. This is an ope
www.molecularmetabolism.comstimulated (10 and 100 nM) GLUT4 translocation following AZD8055
and rapamycin pre-treatment (Figure 6C). To test whether AZD8055
had off-target effects on the glucose transporters we used giant
sarcolemmal vesicles (GSV). In these vesicles glucose transporter
translocation is absent and glucose transport relies solely on the
glucose transporter present in the vesicle plasma membrane.
AZD8055 had no effect on glucose uptake into these vesicles
(Figure 6D), even at a higher concentration than was used in any of the
experiments, while Cytochalasin B had the expected inhibitory effect
(Figure 6D). Together these data indicate that AZD8055 inhibits
glucose uptake in muscle cells independently of GLUT4 translocation
and activity.
3.6. AZD8055 reduces glycolysis by blocking mTORC2 activity
In light of the observed dissociation between normal GLUT4 trans-
location, AS160 phosphorylation, and reduced glucose uptake with
AZD8055 treatment, we hypothesized an intracellular glucose
handling defect. Recent reports have suggested that mTORC2 is a
positive regulator of glycolysis [2,35]. To this end we measured
lactate release into media of mouse embryonic fibroblast cells that
were missing the critical mTORC2 subunit SIN1 (SIN1 KO MEFs) and
two control cell conditions: wildtype (WT) MEFs and SIN1 KO MEFs inn access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/). 633
Figure 2: AZD8055 induces whole-body insulin resistance and impairs mTOR signaling in insulin responsive tissues. (A) Overnight fasted mice were intraperitoneal-injected with
either vehicle or AZD8055 (10 mg kg1), re-fed and mixed tail blood obtained at indicated time-points was analyzed for plasma glucose concentration (n ¼ 5); (B,C) 3 h after
AZD8055 injection additional blood was sampled for plasma insulin and fatty acids (FA) determinations (n ¼ 4e5). (DeG) Representative western blots and quantitative analysis of
mTOR signaling in mouse quadriceps, gastrocnemius, liver, heart, and adipose tissue two hours after vehicle or AZD8055 injection (n ¼ 8; for adipose tissue n ¼ 4). **p < 0.01
different from vehicle at indicated time-point; #p < 0.01 from vehicle; *p < 0.05 different from vehicle within each tissue. Data are means  SEM.
Original articlewhich WT SIN1 was re-introduced (SIN1 KO þ WT). Lactate release
was increased by serum stimulation in WT MEF cells and in SIN1
KO þ WT cells, but no response was observed in SIN1 KO cells
(Figure 6E). AZD8055 treatment diminished lactate release in SIN1 WT
and SIN1 KO þ WT cells, but the Akt inhibitor, MK2206, did not.
Neither drug affected SIN1 KO cells. Thus, impairing mTORC2 activity
either genetically or pharmacologically reduced glycolytic flux in these
cells.
3.7. AZD8055 reduces glucose tolerance by blocking mTORC2
activity in skeletal muscle
In WT mice, AZD8055 injection led to glucose intolerance (Figure 6F,G).
In mice lacking the mTORC2 subunit, Rictor, in skeletal muscle (Ric
mKO), AZD8055 had no effect (Figure 6F,G). Furthermore, vehicle
treated Ric mKO mice exhibited glucose intolerance compared to
vehicle treated Rictor WT mice (Figure 6F,G). This indicates that acute
mTOR inhibition by AZD8055 perturbs glucose tolerance in part by
blocking mTORC2 activity in skeletal muscle.634 MOLECULAR METABOLISM 3 (2014) 630e641  2014 The Authors. Published by Elsevier Gm3.8. In vivo glucose uptake into muscle is impaired in muscle
lacking mTORC2 activity despite normal AS160 phosphorylation
Given the glucose intolerance of Ric mKO mice, which has been re-
ported by others [36], we investigated whether in vivo glucose uptake
into muscle of Ric mKO mice was impaired. To this end we aimed to
mimic a glucose tolerance test. Conscious mice were injected with
saline or a glucose solution spiked with 3H-2-DG to assess glucose
uptake in skeletal muscle. Ric mKO exhibited glucose intolerance
(Figure 7A), with no impairment in glucose-induced insulin release
(Figure 7B). With saline injection, plasma insulin levels were lower at
15 min and returned to baseline levels by 30 min (Figure 7B) in both
Ric WT and mKO mice. Overall glucose clearance (Kg) was w30%
lower in Ric mKO muscle (Figure 7C). Glucose-induced glucose uptake
(Rg), which accounts for the mass action of the plasma glucose con-
centrations, was 30% lower in Ric mKO muscle (Figure 7D). Muscle
glycogen content and muscle free glucose concentrations were
elevated by w24% and w16%, respectively, in Ric mKO muscle
(Figure 7E,F). Phosphorylation of AktSer473 was markedly reduced andbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Figure 3: AZD8055 differentially affects p-AktThr308 and p-AS160 in vivo (A,B) Representative western blots and quantitative analysis of p-AktThr308 and pan-AS160 phos-
phorylation in mouse quadriceps, gastrocnemius, liver, heart, and adipose tissue two hours after vehicle or AZD8055 (10 mg kg1) injection (n ¼ 8, for adipose tissue n ¼ 4).
*p < 0.05 different from vehicle within each tissue. Data are means  SEM.
Figure 4: AZD8055, but not rapamycin, reduces muscle glucose uptake ex vivo. (A,B) Mouse soleus and EDL muscles were incubated ex vivo in the presence of 0.1% DMSO,
640 nM AZD8055 or 1 mM rapamycin for 30 min, followed by basal or insulin (60 nM) stimulation. Glucose uptake was measured with 3H-2-deoxyglucose (n ¼ 7e8). *p < 0.05
different from corresponding DMSO. Data are means  SEM.
MOLECULAR METABOLISM 3 (2014) 630e641  2014 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Figure 5: AZD8055 impairs insulin-stimulated mTOR, but not AS160 signaling ex vivo. (A) Representative Western blots in soleus and EDL muscle. (BeK) Western blotting
quantification of indicated proteins in mouse soleus and EDL muscles that were incubated with either 0.1% DMSO, 640 nM AZD8055 or 1 mM rapamycin for 30 min and basal or
insulin-stimulated (60 nM) ex vivo (n ¼ 7e8). *p < 0.05 different from corresponding basal; #p < 0.05 different from corresponding DMSO; Up < 0.05 main effect of insulin. Data
are means  SEM.
Original articleunresponsive to glucose stimulation (Figure 8B), while p-AktThr308 was
elevated following saline and glucose stimulation in Ric mKO muscle
(Figure 8C). Similarly p-AS160Thr642 was also increased following
saline and glucose stimulation in Ric mKO muscle (Figure 8E).
p-GSK3ßSer9, a readout of Akt activity, was similar in Ric WT and mKO
muscle and responsive to glucose stimulation (Figure 8G). GLUT4,
GSK3-beta and AS160 protein expression were unchanged between
the genotypes (Figure 8F,H,I), while Ric mKO muscle hadw40% less
Akt2 protein (Figure 8D). These data indicate that mTORC2 activity is
necessary for normal muscle glucose uptake in vivo, despite unim-
paired Akt activity, judged by downstream targets.
4. DISCUSSION
We provide in vivo and in vitro evidence that acute mTOR inhibition is
detrimental to whole-body and skeletal muscle glucose metabolism.
The effects on the whole-body include insulin resistance, increased
lipid oxidation and glucose intolerance. The latter is largely due to
blocking skeletal muscle mTORC2 activity. In muscle, acute mTOR
inhibition leads to insulin resistance in vitro, although insulin-
stimulated GLUT4 translocation is normal with AZD8055 treatment in
muscle cells. Rictor deficient muscles exhibit reduced insulin-
stimulated glucose uptake in vivo along with glucose accumulation.
Abrogation of mTORC2 activity by SIN1 knockout or AZD8055 treat-
ment decreased glycolysis in MEF cells. Collectively our data suggest636 MOLECULAR METABOLISM 3 (2014) 630e641  2014 The Authors. Published by Elsevier Gmthat acute mTOR inhibition by AZD8055 or genetic abrogation of
mTORC2 activity impairs glycolysis which reduces insulin sensitivity of
glucose uptake in muscle.
We focused on acute mTOR inhibition with AZD8055, a highly selective
and bioavailable mTOR-KI [23], to investigate experimental outcomes
that stem from acute post-translational signaling changes due to
inhibited mTORC1 and mTORC2 kinase activity. Others have studied the
acute effect of mTORC1 inhibition by rapamycin. In contrast to the acute
effect of AZD8055, acute rapamycin treatment may actually have in-
sulin sensitizing effects. Insulin activates mTORC1 and its substrate
S6K1, which phosphorylates and inhibits the insulin receptor substrate
1 (IRS-1). By blocking mTORC1, rapamycin disrupts this negative
feedback loop and thereby increases IRS-1 activity, which is reflected in
increased Akt activity in adipose and muscle cells [37,38]. In agree-
ment, in humans acute rapamycin-treatment can actually improve
whole-body insulin sensitivity [39]. Our data support this idea, because
in soleus muscle insulin-stimulated p-AktThr308 is enhanced with
rapamycin treatment. When we administered rapamycin we neither
observed substrate changes, nor did we detect an inhibitory effect of
rapamycin on muscle glucose uptake in vitro. Supporting our data,
rapamycin injection in ob/ob mice, at a concentration similar to what we
injected in the present study, had no effect on glucose or insulin
tolerance, despite reducing S6K1 phosphorylation in muscle [40].
Collectively, these data suggest that the detrimental effect of AZD8055
on glucose metabolism is not mediated by mTORC1 signaling.bH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Figure 6: AZD8055 impairs insulin-stimulated glucose uptake but not GLUT4 translocation in muscle cells, blocks lactate release and induces glucose intolerance by blocking
muscle mTORC2. (A,B) Insulin-stimulated 3H-2-deoxyglucose uptake following 50 min of 0.1% DMSO, 500 nM AZD8055 or 100 nM rapamycin pre-incubation in L6-GLUT4myc
myoblasts (n ¼ 3e5). (C) Insulin-induced (10 and 100 nM) GLUT4 translocation in L6-GLUT4myc myoblasts following AZD8055 (500 nM) or rapamycin (100 nM) pre-treatment for
50 min (n ¼ 4). (D) Glucose transport into sarcolemmal giant vesicles pretreated with indicated inhibitors and concentrations (n ¼ 3e4). (E) Overnight lactate release into media
from SIN1 WT, KO and KO þ WT MEFs that were treated with indicated inhibitors and concentrations of serum (n ¼ 3). (F) Glucose concentrations measured from mixed tail blood
at indicated time points in Rictor WT and mKO mice that were intraperitoneal-injected with either vehicle or AZD8055 (10 mg kg1) at t ¼ 120 min and with glucose (2 g/kg) at
t ¼ 0 (n ¼ 8e9). (G) Area under the curve determined from (F) (n ¼ 8e9). #p < 0.001 different from corresponding basal; ¤p < 0.05 different from corresponding DMSO;
*p < 0.05 different from corresponding vehicle; ￥p < 0.05 difference between indicated groups. Data are means  SEM.However, rapamycin does not fully inhibit mTORC1, whereas mTOR
KIs likely do [20]. Evidence for this can also be found in the present
study. AZD8055 inhibited p-S6K1 more effectively than rapamycin in
incubated muscle. Therefore, AZD8055 could affect metabolism by
inhibiting rapamycin-insensitive mTORC1 signaling. However, similar
to acute rapamycin treatment, abrogation of mTORC1 activity by
raptor deletion increases p-Akt in muscle cells and skeletal muscle
[22,38]. Moreover, deletion of raptor in adipose tissue protects mice
from high fat diet induced weight gain and improves their glucose
tolerance [41]. This indicates that inhibited mTORC1 signaling byMOLECULAR METABOLISM 3 (2014) 630e641  2014 The Authors. Published by Elsevier GmbH. This is an ope
www.molecularmetabolism.comAZD8055 likely does not account for the metabolic effects observed by
AZD8055.
Long-term rapamycin treatment has been used to inhibit mTORC1 and
mTORC2 signaling. However, it takes several days for rapamycin to
inhibit both mTOR complexes and this does not affect all tissues
equally [1,14,15,17,18]. Long-term rapamycin treatment in mice also
causes changes in gene transcription, body mass and food intake.
To better understand the effect of AZD8055 on insulin action and
glucose uptake in skeletal muscle we used the in vitro muscle incu-
bation method. Insulin-stimulated glucose uptake was diminished byn access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/). 637
Figure 7: Rictor deficient muscles have impaired in vivo glucose uptake, elevated
glucose and glycogen levels. (A,B) Plasma glucose and insulin levels in Rictor WT and
mKO mice just before (0 min) and 15 and 30 min after glucose or saline injection
(n ¼ 8e9). (C,D) Glucose clearance and uptake into quadriceps muscle of Rictor WT
and mKO mice 30 min after saline or glucose injection (n ¼ 7e8). (E,F) Muscle
glycogen and glucose levels from Rictor WT and mKO mice 30 min after saline or
glucose injection (n ¼ 7e9). ***p < 0.001 and **p < 0.01 effect of time compared to
0 min; #p < 0.05 effect of genotype within glucose stimulation; (#)p < 0.1 effect of
genotype within saline stimulation; ¤p < 0.05 main effect of genotype; *p < 0.05
different from WT glucose stimulation. Data are means  SEM.
Original articleAZD8055. Surprisingly insulin-stimulated GLUT4 translocation was
normal in L6 cells, despite a similar glucose uptake defect as observed
in mature striated muscle. Normal glucose transport into GSV indicates
that AZD8055 has no direct inhibitory effect on the glucose transporter
activity. In agreement with normal GLUT4 translocation observed in
AZD8055-treated L6 myocytes, phosphorylation of AS160, a key
regulator of GLUT4 translocation [33,34] and a well established Akt
substrate, was normal in incubated muscle treated with AZD8055
under both basal and insulin-stimulated conditions. Overall our data
suggest that glucose transport capacity was unaffected by AZD8055,638 MOLECULAR METABOLISM 3 (2014) 630e641  2014 The Authors. Published by Elsevier Gmbecause GLUT4 translocation and activity and the phosphorylation of
the key regulator, AS160, were normal.
Consequently, we explored whether AZD8055 treatment leads to an
intracellular glucose handling defect. In this light it is interesting that
mTORC2 has been reported as a positive regulator of glycolysis in
cancer and liver cells [2,35]. We reasoned that an AZD8055-induced
defect in glycolysis may adversely affect the glucose concentration
gradient necessary for normal glucose uptake and that this is mediated
by blocking mTORC2 activity. In agreement with our hypothesis,
AZD8055 decreased glycolysis judged by lactate release in MEF cells.
Similarly, disruption of mTORC2 activity in MEFs, by knockout of SIN1,
also impaired glycolysis, but this defect was rescued by re-introduction
of wildtype SIN1 protein. Since AZD8055 had no effect on glycolysis in
SIN1 KO MEFs, but reduced glycolysis in wildtype MEFs and in SIN1 KO
MEFs that received wildtype SIN1 protein, we conclude that AZD8055
impairs glycolysis by inhibiting mTORC2 activity. Furthermore, given
that the Akt inhibitor, MK2206, had no effect of glycolysis, AZD8055
and mTORC2 likely impact glycolysis independently of Akt signaling.
Glucose uptake was impaired in Rictor deficient muscles in vivo. Once
again this occurred despite normal Akt activity, but Rictor mKO mus-
cles had increased muscle glucose levels. This glucose build-up is
compatible with an attenuated glycolytic flux and diminishes the
transmembrane glucose gradient explaining the decreased glucose
uptake. The increased glycogen content in Rictor mKO muscle likely
reflects the shunting of glucose into storage, which also fits with a
decrease in glycolytic flux.
Of some debate is whether phosphorylation of Akt Ser473 depends on or
influences Thr308 phosphorylation, and vice versa [32]. In the present
study, acute mTOR inhibition by AZD8055markedly lowered p-AktSer473
without much impact on p-AktThr308 in vivo. In incubated muscles,
p-AktT308 was lower with AZD8055 treatment, but remained insulin
responsive. Abrogation of mTORC2 activity by Rictor deletion in skeletal
muscle also markedly lowered p-AktSer473, but this had no inhibitory
effect on p-AktT308, which has been reported in muscle by others
[22,36]. Deletion of the kinase responsible for Akt Thr308 phosphory-
lation, PDK1, has reportedly no inhibitory effect on p-AktSer473 in liver
and cardiac tissue [42e44]. Together these data indicate that Ser473 or
Thr308 phosphorylation do not influence one another markedly.
Furthermore, the effect of decreased p-AktSer473 on overall Akt activity is
elusive. Judging by in vivo substrates, such as GSK3 and TSC2 phos-
phorylation, Akt activity is largely normal with genetic disruption of
mTORC2 (Rictor or SIN1 KO) and subsequent reduction in p-AktSer473
[3,36,45e47]. In contrast, Akt phosphorylation sites on FoxO1 and
FoxO3a have been found to be impaired with blockade of mTORC2
activity by several groups [3,4,36,45,46]. It remains to be seen whether
reduced p-AktSer473 affects a certain subset of Akt substrates.
The role of mTORC2 in metabolism in mature skeletal muscle in vivo
has not previously been studied. Together with in vitro evidence by
others [36,48], our data suggest that mTORC2 may play a role in
muscle insulin resistance. Although the liver, like muscle, is an
important organ in regulating whole-body glucose homeostasis [49];
and liver mTORC2 activity was inhibited following AZD8055 injection,
the observation that AZD8055-induced glucose intolerance is absent in
Rictor mKO mice indicates that reduced muscle mTORC2 activity ac-
counts for most of the impairment in whole-body glucose metabolism
with acute global mTOR inhibition. In contrast, chronic rapamycin
treatment leads to whole-body insulin resistance by disrupting liver
mTORC2 signaling and increasing liver glucose output [19]. The dif-
ference between our study and the chronic rapamycin study [19] likely
indicates the different responses to acute and chronic inhibition of the
mTOR complexes.bH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Figure 8: Glucose-induced Akt Ser473 phosphorylation is impaired in Rictor deficient muscle, but downstream Akt signaling is intact. (A) Representative western blots for indicated
proteins and phosphorylation sites and (BeJ) their densitometry quantification from muscles of Rictor WT and mKO mice 30 min after saline or glucose injection (n ¼ 8e9).
*p < 0.05 effect of glucose injection compared to corresponding saline group; (¤)p < 0.1 main effect of glucose injection; #p < 0.05 main effect of genotype. Data are
means  SEM.In conclusion, we have shown that acute mTOR inhibition by AZD8055
leads to insulin resistance and glucose intolerance along with changes
in substrate utilization. Insulin-mediated glucose transport into muscle
cells is perturbed despite normal GLUT4 translocation, which points to
an intracellular glucose handling defect. Fittingly, AZD8055 sup-
pressed glycolysis through inhibition of mTORC2, and furthermore
Rictor deficient muscle exhibited impaired in vivo glucose uptake along
with muscle glucose accumulation. These findings warrant future in-
vestigations into the physiological role of mTORC2 in skeletal muscle,
which as a large glucose sink is indispensable for normal glucose
homeostasis. In addition, the severe metabolic consequences following
AZD8055 treatment may limit the clinical usefulness of mTOR-KIs.
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